SR-8541A not checked

Stingray Therapeutics

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
6 active
6 in total · 4 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“SR-8541A administered orally in combination with intravenous botensilimab and balstilimab”In the company’s words, NCT06589440 on ClinicalTrials.gov
Tested for
Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), Advanced / Metastatic Solid Tumor
Main trialPhase 2
“This is an open-label, dose escalation and expansion, multi-center phase 2 study evaluating the safety and efficacy of SR-8541A administered orally in combination with intravenous botensilimab and balstilimab in subjects with MSS-CRC with and without active liver metastases.”In the company’s words, NCT06589440 on ClinicalTrials.gov
Other names
Botensilimab · Balstilimab

Other drugs for Advanced / Metastatic Solid Tumor

All 303 drugs for Advanced / Metastatic Solid Tumor

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 2Recruiting 31 Jul 2027 Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Phase 1Recruiting Dec 2025 A Study of SR-8541A (ENPPI Inhibitor) in Advanced/Metastatic Solid Tumors
Phase 2Authorised not given WINDOW-OF-OPPORTUNITY UMBRELLA PLATFORM TRIAL OF SHORT-COURSE PRE-OPERATIVE OR NEOADJUVANT TARGETED TREATMENT IN PATIENTS WITH MOLECULARLY SELECTED AND RESECTABLE PRIMARY COLORECTAL CANCER: THE UNICORN STUDY
Phase 2Authorised not given Pan-tumor neoadjuvant basket study of immune check-point inhibition and novel IO combinations (NEOASIS)
Phase 3Authorised not given CIME - Combination of Immune checkpoint in locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas : A multicenter, randomised, comparative, open-label Phase III aiming to compare the survival of patients with locally advanced or metastatic MSI/dMMR Esogastric adenocarcinomas treated by a combination of Immune checkpoint inhibitors (botensilimab + balstilimab) versus the standard of care (FOLFOX/XELOX + nivolumab)
Phase 2Authorised not given A phase 2, open label study to evaluate safety and clinical activity of balstilimab in monotherapy in patients with advanced/metastatic non-melanoma skin cancers (AGENONMELA).
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow SR-8541A

Following is part of Solo: you see every change to SR-8541A the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in